With global rights to TTP's soft-mist inhalation platform, Lupin gets access to the drug delivery system used by Boehringer Ingelheim for Spiriva Respimat and it will be interesting to watch pricing as Lupin leverages the aerosolization technology across respiratory products. Meanwhile, the company has entered a partnership with Biomm for marketing its Neulasta biosimilar in Brazil.
Lupin Limited’s recent deal with TTP Plc for its soft-mist inhalation technology platform is expected to provide a leg-up to the Indian firm's respiratory ambitions.
Recently, Lupin Inc., a wholly owned subsidiary, gained exclusive global rights to develop, manufacture and commercialize inhalation products using TTP’s...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
